US5502167A
Expired / Lapsed
US
⏱️ 0.0 years remaining
CDR grafted humanised chimeric T-cell antibodies
Assignee: TOLERX Inc LIQUIDATING TRUST
•
Filing: 1992-12-04
•
Granted: 1996-03-26
•
Expires: 2012-12-04
Abstract
Abstract A humanised antibody is provided in which the amino acid sequence of the CDRs is derived from the sequence of CDRs of a monoclonal antibody having the specificity of binding to resting and activated T-cells, inhibiting T-cell proliferation and lysing T-cells from mice transgenic for human CD2 and in which sufficient of the amino acid sequence of each CDR has been retained to provide the same specificity for the humanised antibody.
Inventors
- 👤 Herman Waldmann
- 👤 Louise Walsh
- 👤 James S. Crowe
- 👤 Alan P. Lewis
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-04 05:56
CPC Classifications
C; C07; C07K; C07K16/00; C07K16/18; C07K16/28; C07K16/2803; C07K16/2806; A; A61; A61P; A61P37/00; A61P37/02; A61P37/06; A61K; A61K38/00; C07K2317/00; C07K2317/20; C07K2317/24; Y; Y10; Y10S; Y10S530/00; Y10S530/867
Claims Analysis
Total Claims: 7
Claim 1
Independent Claim
162 words
A humanised antibody that specifically binds resting and activated T-cells, inhibits T-Cell proliferation and lyses T-cells from mice transgenic for human CD2, the heavy and light chain variable domains of said antibody are composed of framework and complementary determining regions, wherein light chain complementary determining region 1 has the amino acid sequence set forth in SEQ ID NOs. 3 or 4, light chain complementary determining region 2 has the amino acid sequence set forth in SEQ ID NOs. 5 or 6, light chain complementary determining region 3 has the amino acid sequence set forth in SEQ ID NOs. 7 or 8, heavy chain complementary determining region 1 has the amino acid sequence set forth in SEQ ID NOs. 11 or 12, heavy chain complementary determining region 2 has the amino acid sequence set forth in SEQ ID NOs. 13 or 14, and heavy chain complementary determining region 3 has the amino acid sequence set forth in SEQ ID NOs. 15 or 16.
Claim 2
Dependent Claim
162 words
A humanised antibody that specifically binds resting and activated T-cells, inhibits T-Cell proliferation and lyses T-cells from mice transgenic for human CD2, the heavy and light chain variable domains of said antibody are composed of framework and complementary determining regions, wherein light chain complementary determining region 1 has the amino acid sequence set forth in SEQ ID NOs. 3 or 4, light chain complementary determining region 2 has the amino acid sequence set forth in SEQ ID NOs. 5 or 6, light chain complementary determining region 3 has the amino acid sequence set forth in SEQ ID NOs. 7 or 8, heavy chain complementary determining region 1 has the amino acid sequence set forth in SEQ ID NOs. 11 or 12, heavy chain complementary determining region 2 has the amino acid sequence set forth in SEQ ID NOs. 13 or 14, and heavy chain complementary determining region 3 has the amino acid sequence set forth in SEQ ID NOs. 15 or 16.
Claim 3
Dependent Claim
30 words
An antibody according to claim 1, in which the framework region of the light chain variable domain is substantially homologous to the variable domain framework region of the protein HSIGKV11.
Claim 4
Dependent Claim
30 words
An antibody according to claim 1, in which the framework region of the heavy chain variable domain is substantially homologous to the variable domain framework region of the protein KOL.
Claim 5
Dependent Claim
18 words
A DNA sequence encoding the light chain or the heavy chain of the humanised antibody of claim 1.
Claim 6
Dependent Claim
13 words
An expression vector which incorporates a DNA sequence as claimed in claim 4.
Claim 7
Dependent Claim
13 words
A host cell transformed with an expression vector as claimed in claim 5.
References Cited (Backward Citations)
EP0239400A2
Cited
WO1988009344A1
Cited
WO1990008187A1
Cited
WO1991009967A1
Cited
WO1991009968A1
Cited
WO1993011237A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1999-03-26 | 1999-09-25 | 2000-03-26 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2003-03-26 | 2003-09-25 | 2004-03-26 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2007-03-26 | 2007-09-25 | 2008-03-26 | $7700.00 | Window Closed / Lapsed |